Clinical trials: Type 2 Diabetes, completed
Diabetes Mellitus, Type 2
A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin
This study will assess safety and tolerability of metformin plus GSK189075 in people with Type 2 Diabetes. About 48 people will participate in this study. Volunteers will not know if they are receiving GSK189075 or a placebo.
- Trial name
- NCT00519480
- Testing
- GSK189075, Metformin
- Where
- 4 sites in United States, Argentina and 1 more
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Family Model Diabetes Self-Management Education in Faith Based Organizations
This study's objective is to conduct a cluster randomized control study that evaluates the effectiveness of F-DSME (Family Model Diabetes Self-Management Education) when delivered in a group setting in Marshallese Faith Based…
- Trial name
- FDSMEFBO (NCT04256486)
- Testing
- Family Model Diabetes Self-Management Education and Support
- Where
- United States
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Sleep Apnea
CPAP in Diabetes Type 2 Patients With Sleep Apnea
Aim: To assess if six months of treatment with CPAP associated with conventional drug therapy, contribute to improved glycemic control in patients with type 2 diabetes and sleep apnea-hypopnea syndrome SAHS)
- Trial name
- DM-SAHS (NCT01801150)
- Testing
- CPAP nasal treatment
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Hospital Universitario La Paz
Prediabetic State
Evaluation of the Translation of the DE-PLAN Program for the Primary Prevention of Type 2 Diabetes in Routine Primary Care
The purpose of this study is to evaluate the feasibility and effectiveness of the DE-PLAN Euskadi program for the primary prevention of type-II diabetes in high-risk population seen in primary care centers (Osakidetza-Basque…
- Trial name
- DE-PLAN E (NCT01365013)
- Testing
- DE-PLAN, Control group
- Where
- Spain
- Volunteers
- 1,113 people
- Sponsor
- Basque Health Service
Type II Diabetes Mellitus
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus
The purpose of this study is: to assess clinical efficacy of Subetta in the combined treatment of type II diabetes mellitus; to assess safety of Subetta in the combined treatment of type II diabetes mellitus.
- Trial name
- NCT01868646
- Testing
- Subetta
- Where
- 17 sites in Russia
- Volunteers
- 190 people
- Sponsor
- Materia Medica Holding
Diabetes Mellitus (Type 2), Inflammation
Probiotic Effects in Type 2 Diabetes
Adult-onset diabetes is a disease characterized by high blood glucose levels and is one of the leading causes of cardiovascular disease, blindness, end-stage renal failure, and hospitalization.
- Conditions
- Diabetes Mellitus (Type 2), Inflammation, Probiotics, Antioxidant Effect
- Trial name
- NCT07330388
- Testing
- Probiotic group
- Where
- Turkey (Türkiye)
- Volunteers
- 77 people
- Sponsor
- Ege University
Diabetes
Protein Hydrolyzation and Glycemic Control
The insulinotropic effects of protein hydrolysate/amino acid ingestion have been shown to regulate blood glucose homeostasis in both type 2 diabetes patients and normoglycemic controls.
- Trial name
- NCT01034618
- Testing
- Protein hydrolyzation
- Where
- Netherlands
- Sponsor
- Maastricht University Medical Center
Type 2 Diabetes Mellitus (T2DM)
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
Primary objective: Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice Secondary objective: Treatment satisfaction
- Trial name
- ELDERLY-T (NCT05607160)
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Sanofi
Type 2 Diabetes
Self-care Management Programme for Type 2 Adult DM Patients With Poor Glycemic Control
Type 2 diabetes becomes the most prevalence chronic disease worldwide. Most type 2 diabetes patient are under the care in public general out-patient clinic in Hong Kong.
- Trial name
- T2DM (NCT04092023)
- Testing
- nursing education
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Dyslipidemia Associated With Type II Diabetes Mellitus
Type 2 Diabetic Patients Maintained on Statin Therapy
Patients with diabetes mellitus (DM) are at increased risk of atherosclerotic cardiovascular disease (ACVD). The achievement of the LDL-C target with statins for the reduction of ACVD risk is recommended.
- Trial name
- NCT03784703
- Testing
- Atorvastatin 40 Mg Oral Tablet, Rosuvastatin 10 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 160 people
- Sponsor
- Damanhour University
Type 2 Diabetes Mellitus
A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers
This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 and to investigate the effect of food on the pharmacokinetics of DA-1229_01 in healthy male volunteers
- Trial name
- NCT02167061
- Testing
- DA-1229_01, E+M, DA-1229_01 fast
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Coronary Artery Disease, Type 2 Diabetes Mellitus
Comparison Between Pioglitazone and SES With type2 DM
Drug-eluting stents have been shown to decrease restenosis, but were associated with an increased rate of death, as compared with bare-metal stents.
- Trial name
- NCT00482183
- Testing
- Pioglitazone
- Volunteers
- 38 people
- Sponsor
- Showa University
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus
the pharmacokinetics, pharmacodynamics and safety and tolerability of single and multiple oral doses of BI 10773 at low dose once daily (q.d.) and high dose q.d.
- Trial name
- NCT01316341
- Testing
- BI10773
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Vascular Function, Fish Protein Hydrolysates and Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease of abnormal carbohydrate metabolism which is related with high morbidity and mortality rates caused by its complications.
- Trial name
- NCT03318913
- Testing
- Fish protein hydrolysates
- Where
- Brazil
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio de Janeiro
Type 2 Diabetes Mellitus
A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02419859
- Testing
- PaQ® Insulin Delivery Device, Insulin, Asp(B28)-
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- CeQur Corporation
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus
The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- SAMS12 (NCT00495885)
- Testing
- volinanserin (M100907)
- Where
- 16 sites in United States, Brazil and 14 more
- Volunteers
- 848 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Obesity, Type 2 Diabetes
GOAL Life-Style Change Intervention to Prevent Type 2 Diabetes
Life-style change achieved in controlled experimental condition has been shown to prevent type 2 diabetes. The purpose of this study is to evaluate to what extent the life-style change can be achieved in a routine health care…
- Trial name
- NCT00398060
- Testing
- Cognitive-behavioral life-style counseling
- Where
- Finland
- Volunteers
- 389 people
- Sponsor
- Finnish Institute for Health and Welfare
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.